Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05419726 · ClinicalTrials.gov registry record
Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.
A clinical trial of Obesity, sponsored by University of California, Los Angeles.
- Recruiting
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT05419726 is a study of Obesity that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 20 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05419726, a study of Obesity, is actively recruiting participants, sponsored by University of California, Los Angeles.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Glucagon like peptide (GLP-1) agonists, such as liraglutide, exenatide, and semaglutide, have been increasingly used as a medication to address the current twin epidemics of diabetes and obesity. Their activities include increasing insulin production by pancreatic beta cells, improving insulin sensitivity in muscles and weight loss. The mechanisms underpinning the weight loss caused by GLP-1 agonists have not yet been fully elucidated, but brown adipose tissue (BAT) appears to play an important role. We propose to assess BAT activity, using infrared thermography camera images, before individuals start weekly administration of semaglutide, at week 2-4, and week 18-20. We hypothesize that this GLP-1 agonist, semaglutide, will cause an increase in BAT activity and a corresponding increase in basal metabolic rate.
Conditions Studied
Interventions
- DRUG Semaglutide Injectable Product (not provided by the study)
Study Locations (1)
California
- UCLA Health - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-02-01 |
| Est. Completion | 2026-02-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05419726
The ClinicalTrials.gov registry entry for NCT05419726 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (98% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which Semaglutide Injectable Product (not provided by the study) is the first listed.
NCT05419726 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05419726 about?
NCT05419726 is a clinical study titled "Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.". Glucagon like peptide (GLP-1) agonists, such as liraglutide, exenatide, and semaglutide, have been increasingly used as a medication to address the current twin epidemics of diabetes and obesity. Their activities include increasing insulin production by pancreatic beta cells, improving insulin sensi...
What is the current status of trial NCT05419726?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2023-02-01. Estimated completion is 2026-02-01.
What conditions does trial NCT05419726 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT05419726?
The interventions under investigation include: Semaglutide Injectable Product (not provided by the study) (DRUG).
Who is sponsoring clinical trial NCT05419726?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05419726 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial
RECRUITING · NA
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Tai Chi as a Novel Strategy to Increase Physical Activity Among Adults Pursuing Metabolic and Bariatric Surgery
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.